van Besouw NM, van der Mast BJ, Smak Gregoor PJ, et al: Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 14:2710-2713, 1999van Besouw NM, van der Mast BJ, Smak Gregoor PJ, et al...
Use LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids. ( 2.3) Modify the LUPKYNIS dose based on eGFR ( 2.3, 5.3): Assess eGFR every two weeks for the first month, every four weeks through the first year, and quarterly thereafter. If eGFR <60 mL/min/1.73 m2 ...
PHARMACOKINETICS OF TOTAL AND FREE MYCOPHENOLIC ACID (MPA) W...An abstract is unavailable. This article is available as a PDF only.GrinyoJ;EkbergH;OppenheimerF;PlumedJ;RodriguezG;HernandezD;KuypersD;BrunetTransplantation
Use LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids [seeClinical Studies]. Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. Dosage of LUPKYNIS is based on the patient...
ACY-1 was one of 75 urinary proteins changing significantly in rats treated with cyclosporine or sirolimus (but not tacrolimus)-treated rats,35 and ACY-1 forms adducts with the biologically active metabolite generated in the kidney from mycophenolate mofetil,36 proposed to be involved in organ ...
Mycophenolic acid (MPA), the active metabolite of the immunosuppressant mycophenolate mofetil (MMF), is primarily metabolized by glucuronidation to a phenolic glucuronide (MPAG) and an acyl glucuronide (AcMPAG). It is known that AcMPAG, which may be an immunotoxic metabolite, is deglucuronidated...
Mesangial cells-mediated glomerulonephritis is a frequent cause of end-stage renal disease. Here, we show that celastrol is effective in treating both reversible and irreversible mesangioproliferative glomerulonephritis in rat models, but find that its o
likely to require a lower dose than younger patients to achieve the same efficacy [76,77]. Conversely, elderly patients may require higher doses of mycophenolate than younger patients owing to a generally lower serum albumin level resulting in a higher clearance of unbound mycophenolic acid [78]...
Mycophenolate mofetil (MMF) at a fixed dose of 2 g/day has been approved for the prevention of kidney allograft rejection in adults. The complex pharmacokinetics of MMF mean that actual exposure to the active metabolite of the drug (mycophenolic acid or MPA) can vary substantially between ...
#2047 Trough-level guided dosing is reliable for mycophenolate mofetil but not for enteric-coated mycophenolic sodiumdoi:10.1093/ndt/gfae069.998BACKGROUND AND AIMS. While trough level (TL) guided dosing is usus for calcineurin inhibitors, mycophenolic acid (MPA) was marketed as a one-size-fits-...